Business Context and Reporting Period
This Form 8-K Current Report was filed by Nanoviricides, Inc. on October 18, 2007, reporting events that occurred on October 16, 2007. The company is incorporated in Nevada and maintains its principal executive offices in West Haven, Connecticut.
Key Financial Metrics and Transaction Details
The filing details a private placement transaction rather than standard periodic financial results. Key metrics from the transaction include:
- Capital Raised: $1,750,000 aggregate purchase price.
- Equity Issued: 3,500,000 shares of common stock (par value $0.001).
- Warrants Issued: Warrants to purchase 1,050,000 shares of common stock.
- Warrant Terms: Exercise price of $1.00 per share; exercisable at any time; expire in three years.
- Implied Price: $0.50 per share for the common stock sold.
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes
The primary material change is the increase in outstanding equity and potential future equity through the issuance of shares and warrants. The securities were sold to certain investors in reliance on exemptions from registration under Section 4(2) of the Securities Act and Rule 506. The investors represented they are "accredited investors" and acquired the securities for their own account.
Outlook, Risks, and Contingencies
Restrictions on Resale: The securities issued are deemed "restricted securities" and bear legends to that effect. They may not be resold or offered in the United States without registration or an applicable exemption from registration.
Management Commentary: The filing contains no forward-looking guidance, outlook, or management commentary regarding future operations or financial performance beyond the description of the transaction.
Investor Verification Checklist
- Verify the total number of outstanding shares post-transaction to assess dilution impact.
- Confirm the identity of the "certain investors" if disclosed in subsequent filings or press releases.
- Review the company's cash position to determine how the $1.75 million proceeds will be utilized.
- Check for any subsequent filings regarding the exercise of the 1,050,000 warrants.